Does Progyny, Inc. (PGNY) have an economic moat?

MoatScan AI rates Progyny, Inc. (PGNY) 52/100 for moat strength, assessed across five sources of competitive advantage: network effects, switching costs, intangible assets, cost advantages and efficient scale. Progyny is a specialized fertility and family-building benefits manager with a legitimate, but limited, competitive position.

What is Progyny, Inc.'s moat score?

Progyny, Inc. (PGNY) has a moat score of 52/100. The score is a weighted average of five pillar ratings: network effects, switching costs, intangible assets, cost advantages, and efficient scale. A higher score means the competitive advantages MoatScan AI identifies are wider and more durable.

Is PGNY stock overvalued or undervalued?

MoatScan AI answers this by estimating PGNY's intrinsic value with a discounted cash flow (DCF) model, then comparing that estimate to the current market price. A share price meaningfully below the estimate is flagged undervalued; meaningfully above it, overvalued. The estimate updates with each new financial analysis.

What is Progyny, Inc.'s fair value estimate?

MoatScan AI derives Progyny, Inc.'s (PGNY) fair value per share from a discounted cash flow (DCF) model built on the company's reported financials, analyst growth forecasts, and a discount rate reflecting its cost of capital. The Financial Analysis tab shows the estimate alongside every assumption behind it.

Back to Database

PGNY$25.96

Progyny, Inc.

Last Updated

Aug 21, 2026about 4 hours ago

Moat & Trend

Management

AI Impact

Competitive Radar

Moat Score

52/100

Executive Summary

Progyny is a specialized fertility and family-building benefits manager with a legitimate, but limited, competitive position. Its Smart Cycles model, care advocacy, pharmacy coordination, and employer-focused benefit design create meaningful differentiation versus generic benefits administrators. The company also operates in a niche where employer trust, clinical execution, and provider relationships matter. However, the business is still highly contractable, with employers able to compare vendors and switch at renewal. The Amazon loss underscores that even large, prominent customers can move away when rivals offer a compelling package. Progyny’s moat is therefore narrower than a broad platform or natural monopoly, and the recent competitive backdrop points to some erosion rather than strengthening. The company remains relevant and differentiated, but not insulated.

Network Effects

Limited Ecosystem Pull

Pillar Strength

4/10

Progyny benefits from a modest ecosystem effect rather than a true network effect. As more employers adopt fertility benefits, the category becomes more normalized, and more providers are willing to work with the company’s benefit design and care model. That can improve member experience and provider familiarity. However, the value for any single employer does not rise dramatically because other employers also participate, and patients do not create meaningful cross-side reinforcement. Clinics can contract with multiple vendors, and employers can compare alternative fertility platforms without losing access to a unique user community. The result is a light reinforcement loop, not a durable network moat.

Switching Costs

Moderate Contract Friction

Pillar Strength

6/10

Switching costs are meaningful but far from prohibitive. Once an employer adopts Progyny, there is onboarding work, employee communication, plan design integration, care navigation setup, and ongoing coordination with fertility providers and specialty pharmacies. Members in active treatment can also create transition risk if benefits change mid-cycle, which gives incumbency some protection at renewal. Still, the relationship is ultimately a benefits contract, usually re-evaluated by procurement and HR teams on a regular basis. The Amazon transition to another fertility-benefits provider is a strong reminder that these accounts can move when price, product, or service execution shifts. Friction exists, but it is manageable.

Intangible Assets

Specialized Brand Know-How

Pillar Strength

6/10

Progyny owns a recognizable specialist brand in employer fertility benefits and has built proprietary know-how around benefit design, patient navigation, and coordination of treatment and pharmacy services. Its early entry into the category and long operating history likely help with credibility in enterprise sales, where trust matters. The company’s data on utilization, outcomes, and member engagement also supports product refinement. But these assets are not protected by strong patents or exclusive licenses, and the brand is not so dominant that competitors cannot win large accounts. In practice, the advantage is mostly execution-based and accumulated through specialization, not legally entrenched.

Cost Advantages

Scale Without Deep Edge

Pillar Strength

5/10

Progyny has scale benefits from spreading administrative, technology, and clinical-support costs across a large and growing employer base. Covering millions of employees and dependents should lower some per-member fixed costs and improve bargaining leverage with specialty pharmacies and providers. Even so, the model is service-intensive rather than asset-heavy, so scale does not create the kind of steep cost advantage seen in manufacturing or logistics. Competitors can assemble similar digital workflows and outsource many clinical functions. The company may run somewhat leaner than a new entrant, but the cost gap appears modest, and there is no clear evidence of a durable structural price advantage.

Efficient Scale

Niche But Contestable

Pillar Strength

5/10

Progyny operates in a specialized niche that is large enough to support only a limited number of national players, which gives it some efficient-scale characteristics. Employers want a credible, clinically informed vendor with broad provider access, and those trust and implementation hurdles can slow entry. Yet the market is not a natural monopoly, and it does not appear so concentrated that one provider can serve all demand efficiently. Rival platforms have still managed to win well-known enterprise accounts, proving that the market can sustain more than one viable participant. The structure favors a handful of specialists, but it does not block new competition or guarantee long-term dominance.

Moat Type & Trend

Why this company earns its moat rating, and where the moat is heading

Moat Type

Narrow Moat

Trend

Negative

Why This Rating

Progyny deserves a Narrow Moat because its advantage is real but not self-reinforcing enough to look impregnable over a 20-year horizon. The company has a differentiated fertility-benefits product, clinical-navigation expertise, and employer relationships that make it a preferred specialist. Yet employers can and do rebid these benefits, and the Amazon defection shows that marquee accounts can leave when another vendor offers an acceptable alternative. That means Progyny is not protected by the kind of exclusive asset, network lock-in, or market structure that would make its position hard to contest across an entire cycle.

Why This Trend

The moat trend is negative because the business has recently shown more contestability than compounding strength. The loss of Amazon, historically a very large account, demonstrates that even scaled enterprise customers are willing to switch providers. In addition, utilization was pressured by regulatory uncertainty around IVF and related services, which exposed how sensitive demand can be to external events. For the trend to turn positive, Progyny would need to show durable retention of large accounts, stronger cross-sell into broader women’s health, and evidence that its service bundle reduces churn rather than merely differentiating bids.

Management Quality Assessment

Evaluating leadership track record, capital allocation, and governance

Verdict

Strong

CEO Pete Anevski has led Progyny since early 2020, giving him a solid but not yet long operating record. Under his tenure the company has expanded rapidly, launched new offerings, and kept returns on invested capital in the mid-teens, suggesting reasonably disciplined execution. Capital allocation has been shareholder-friendly: Progyny has no dividend, but it has used excess cash for buybacks, reducing shares outstanding roughly 9.5% from FY2023 to FY2025, while making small bolt-on acquisitions such as Apryl and BenefitBump that extend the core platform. The company is not founder-led. Insider ownership appears meaningful but modest at about 1.7%, and the direction of change is unclear. CEO pay around $7.2 million looks high versus similarly sized peers, though governance is clean with a majority-independent board and fully independent committees.

Key Highlights

Pete Anevski has served as CEO since early 2020 and has overseen rapid expansion without obvious strategic missteps. The business has continued to grow while maintaining mid-teens ROIC, indicating decent operating discipline.
Progyny has prioritized buybacks over dividends and cut shares outstanding by about 9.5% between FY2023 and FY2025. That said, quarterly repurchases recently exceeded free cash flow, so the pace should be watched.
Recent acquisitions have been small and strategically aligned rather than transformational bets: Apryl expanded global fertility services, and BenefitBump added parental-leave navigation to the member journey.
Insiders own about 1.7% of the company, which provides some alignment but is not especially high. The trend in insider ownership is not clear from available data.
Governance appears sound: the board is majority independent and the audit, compensation, and nominating committees are composed entirely of independent directors.

AI Impact Assessment

Evaluating how AI strengthens or disrupts existing moat pillars

AI Opportunity

6/ 10

AI Threat

6/ 10

Net AI Impact

0Neutral

Net Pressure. AI is most relevant to Progyny’s service and data moat, not its core market demand: the company can use AI to automate authorizations, lab orders, and benefit-design workflows, while Care Advocates use insights to personalize journeys and reduce waste. That should improve operating efficiency and reinforce the bundled experience. However, the strongest moat pillars remain human-led care, a curated specialist network, and outcomes-based benefit design; these are only modestly expanded by AI. The key risk is that generic cloud AI and off-the-shelf analytics can replicate much of the administrative and matching layer, especially for insurers and broader benefits platforms. Near-term uncertainty centers on whether Progyny’s proprietary outcomes data and integrated service bundle stay meaningfully harder to copy than the software layer alone.

AI Opportunity Highlights

Progyny says it is the only fertility solution independently validating all fertility clinical outcomes across all member data by Milliman, creating proprietary outcome records that can improve AI-driven care optimization.
AI embedded in Care Advocate workflows can deepen personalization across fertility, pregnancy, parenting, and menopause journeys, strengthening member retention rather than replacing the human model.
Automation of authorizations, lab orders, and benefit-design tasks can lower operating friction in Progyny’s bundled benefits platform and support scaling into broader women’s health.
Integrated Progyny Rx and a curated specialist network generate cross-utilization data that can improve matching and care navigation in a way point solutions struggle to replicate.

AI Threat Highlights

Generic cloud AI and off-the-shelf analytics are increasingly accessible to insurers and new benefits vendors, lowering barriers to copying Progyny’s workflow layer.
AI can commoditize member matching, utilization analytics, and administrative automation, reducing differentiation versus broader health-benefits ecosystems.
Because Progyny competes against insurer-integrated and broader women’s-health alternatives, AI-enabled incumbents can bundle similar digital guidance into larger contracts and pressure pricing power.

Sign in to see the full analysis

The Strategic Factor Breakdown, Management Quality Assessment, and AI Impact Assessment are available to registered users — it's free.

Last Updated

Aug 21, 2026about 4 hours ago

Target Price

Analyst Consensus

FAIR VALUE

Financial Strength

Financial Score

73/100

Executive Summary

Progyny’s most notable strength is its resilient cash generation, supported by a conservative balance sheet and steadily improving operating profitability. Revenue growth remains constructive, though it has slowed from the FY2023 surge to low-single-digit TTM expansion, while gross and operating margins have continued to widen, indicating effective scaling despite softer top-line momentum. Earnings quality is less uniform, as net income has been affected by tax volatility and other income items, creating some divergence from the stronger operating trends. Liquidity remains ample, with modest leverage and comfortable coverage of current obligations, even though cash balances and working capital have fluctuated. Free cash flow has stayed robust, aided by limited capital intensity and disciplined capital allocation. Overall, Progyny presents as a financially resilient healthcare services company with healthy profitability, strong liquidity, and positive growth visibility, tempered by moderating revenue momentum and some earnings inconsistency, consistent with its solid mid-to-high 7/10 ratings.

Income Statement

Revenue · Margins · Profitability

Section Score

7/10

Assuming Progyny is a healthcare benefits/services company, its revenue trend is solid but slowing: growth jumped in FY2023, then decelerated to 7%–10% in FY2024–FY2025, with TTM revenue up only 1.7% versus FY2025. Profitability has improved more steadily, with gross margin expanding from about 21% to nearly 25% and operating margin rising from 3% in FY2022 to 8.6% TTM. Net income is less consistent because tax expense and other income/expense moved materially, including a large FY2023 other-income benefit and higher tax rates since FY2024. Compared with typical healthcare services peers, margins are healthy and scaling is evident, but slower top-line momentum and tax sensitivity are notable risks.

Financials are in millions USD unless otherwise specified

Metric	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	1,310.764	1,288.661	1,167.221	1,088.598	786.913	—
Revenue Growth	1.72%	10.40%	7.22%	38.34%	—	—
Net Income	78.633	58.52	54.336	62.037	30.358	—
Net Income Growth	34.37%	7.70%	-12.41%	104.35%	—	—

Data as of Jun 30, 2026

Balance Sheet

Assets · Liabilities · Equity

Section Score

7/10

Progyny’s balance sheet remains solid overall, with liquidity well above near-term obligations. TTM cash and short-term investments of $236.9 million exceed total current liabilities of $240.1 million only narrowly, but total current assets of $513.0 million still provide adequate coverage and working capital of $272.9 million. Total debt is modest at $22.5 million, keeping leverage low relative to total assets of $715.8 million and equity of $453.3 million. Equity has generally trended higher over the period, though it fell from $553.4 million in FY2023 to $422.1 million in FY2024 before recovering. The main caution is balance sheet volatility, with current assets and cash balances swinging year to year, but solvency remains comfortable.

Financials are in millions USD unless otherwise specified

Metric	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Total Current Assets	513.018	551.775	472.721	640.407	433.856
Total Assets	715.836	742.435	607.102	756.62	542.986
Total Current Liabilities	240.084	202.391	168.627	185.95	159.536
Total Liabilities	262.579	226.391	185.04	203.191	166.018

Data as of Jun 30, 2026

Cash Flow Statement

Operations · Investing · Financing

Section Score

7.5/10

Progyny shows strong cash generation overall, with operating cash flow rising from $80.4 million in FY2022 to $210.2 million in FY2025, while TTM CFO was still solid at $201.2 million. Free cash flow has stayed healthy as well, increasing from $77.2 million to $191.8 million, with TTM FCF of $178.4 million after higher capital spending. Capex remains modest relative to cash generation, though it stepped up to $18.4 million in FY2025 and $22.9 million TTM. Cash quality is acceptable, but stock-based compensation is high and working capital moved around, especially other working capital. Capital allocation appears shareholder-focused through buybacks, with no debt or dividends.

Financials are in millions USD unless otherwise specified

Metric	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Operating Cash Flow	201.248	210.192	179.105	188.814	80.395
Operating Cash Flow Growth	-4.26%	17.36%	-5.14%	134.86%	—
Free Cash Flow	178.384	191.782	173.7	185.17	77.154
Free Cash Flow Growth	-6.99%	10.41%	-6.19%	140.00%	—

Data as of Jun 30, 2026

Key Ratios

Liquidity · Leverage · Efficiency · Returns

Section Score

7.5/10

Progyny shows very strong liquidity, with current and quick ratios consistently above 270x and cash coverage also ample, indicating no near-term funding stress. Leverage is minimal, with debt to equity staying around 0.02–0.05, so the balance sheet remains conservative. Efficiency is solid: asset turnover improved materially from FY2022 to FY2024 and remains healthy in the latest period, suggesting good use of assets. Profitability is mixed but generally constructive. Operating and pre-tax margins have trended higher over time, while net margin has been more uneven. ROE and ROA remain respectable, though not perfectly stable, supporting an overall picture of a financially resilient business with a few margin consistency issues.

Ratios are dimensionless unless otherwise noted

Metric	Current	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	—	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Current Ratio	272.628	272.628	280.335	344.397	271.949
Quick Ratio	272.628	272.628	280.335	344.397	271.949
Profit Margin	4.54%	4.54%	4.66%	5.70%	3.86%
After Tax ROE	11.34	11.34	12.874	11.21	8.053
Return on Assets	10.98%	7.88%	8.95%	8.20%	5.59%
Debt to Equity	0.05	0.05	0.05	0.04	0.02
P/E Ratio	28.22	41.42	28.75	72.9	74.17
Forward P/E	11.19	12.77	10.99	53.19	—

Data as of Dec 31, 2025

Growth

Revenue · EPS · Valuation · Estimates

Section Score

7.5/10

Progyny shows a clear growth profile: revenue rose from 0.79B USD to 1.09B USD, then to 1.17B USD and 1.29B USD, with the forward estimates extending that climb to 1.38B USD and 1.51B USD. The pattern points to steady compounding after an early surge, with growth settling into a more moderate but still constructive pace. EPS has been more uneven historically, but the analyst forecast implies a sharper earnings expansion over the next two years, with EPS growth of 10.22% and 11.02%, suggesting margin leverage rather than just top-line growth. Sentiment is firmly positive: Strong Buy consensus, a 27-40 USD target range, and 12 analysts provide solid confidence, with the mix tilting slightly more favorable in recent months.

Analyst Price Targets

Low$27+4.01%

Median$35+34.82%

Average$34+30.97%

High$40+54.08%

Strong BuyConsensus rating based on analyst coverage

12 analysts

Recommendation Trends

Rating	Aug '26	Jul '26	Jun '26	May '26
Strong Buy	1	1	2	2
Buy	9	8	8	8
Hold	2	2	1	1
Sell	0	0	0	0
Strong Sell	0	0	0	0
Total	12	11	11	11

Forecast · Analyst Estimates

Revenue This Year1.38B

+6.74%from 1.29B

FY 2026

Revenue Next Year1.51B

+9.92%from 1.38B

FY 2027

EPS This Year· non-GAAP adj.2.08

+10.22%

FY 2026

EPS Next Year· non-GAAP adj.2.31

+11.02%

FY 2027

Historical · Reported Actuals

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Revenue	1.29B	1.17B	1.09B	0.79B	—
Revenue Growth	+10.40%	+7.22%	+38.34%	—	—
EPS (GAAP diluted)	0.65	0.57	0.62	0.30	—
EPS Growth	+14.04%	-8.06%	+106.67%	—	—

Revenue in USD · EPS per share · Price targets in USD

Data as of Dec 31, 2025 · Forecast EPS is analyst non-GAAP adjusted; historical EPS is GAAP diluted — not directly comparable.

Fair Value Estimation

DCF · +67.9% Margin of Safety · Undervalued

AI Fair Value Estimate (DCF)

$43.58vs$25.96

Margin of Safety+67.9%

Undervalued — Margin of safety detected

A DCF framework is appropriate here because Progyny’s model is cash-generative and the operating ramp is reasonably projectable, allowing valuation to be anchored in the evolution of free cash flow rather than near-term accounting earnings. The cash-flow path points to a business that scales from thin initial FCF to materially stronger generation by year five, implying improving margins, disciplined capex, and a gradual fade from high growth toward a more mature terminal profile.

AI Valuation Verdict

A discounted cash flow lens fits Progyny because the business shows a clear multi-year operating ramp and a credible path from modest early free cash flow to stronger cash generation over time. Using a 6.7% discount rate, 2% terminal growth, 18.28% revenue CAGR, 11.61% average EBITDA margin, and 0.61% capex-to-revenue, the model produces a fair value of $43.58 per share versus a current price of $25.96. That implies a 67.87% margin of safety and supports an undervalued verdict. The result is most sensitive to discount rate, terminal growth, and margin durability; stronger pricing leverage or sustained margin expansion would reinforce upside, while weaker growth or compression would narrow it.

DCF Assumptions

WACC

6.7%

Weighted avg cost of capital

Revenue Growth (5Y)

18.3%

CAGR assumption

EBITDA Margin

11.6%

Steady-state projection

CapEx / Revenue

0.6%

Capital investment

Terminal Growth

2.0%

Long-run growth rate

Projection Period

5 yrs

Explicit forecast horizon

Projected Cash Flows

Values in millions USD

Year	Revenue	EBITDA	FCF	Discounted FCF
Yr 1	1,332	116	24	22
Yr 2	1,617	165	68	60
Yr 3	1,964	229	111	91
Yr 4	2,279	298	131	101
Yr 5	2,607	376	192	139
Terminal Value (PV)				3,013

Sign in to see the full analysis

The Income Statement, Balance Sheet, Cash Flow, Key Ratios, Forecast, and Fair Value analysis are available to registered users — it's free.

Sign In to Run AI-Powered Technical Analysis

Create a free account to run a fresh technical analysis across three timeframes — short, medium, and long term.

Frequently asked questions about Progyny, Inc.

Does Progyny, Inc. (PGNY) have an economic moat?: MoatScan AI rates Progyny, Inc. (PGNY) 52/100 for moat strength, assessed across five sources of competitive advantage: network effects, switching costs, intangible assets, cost advantages and efficient scale. Progyny is a specialized fertility and family-building benefits manager with a legitimate, but limited, competitive position.Sign in free to see the Moat Type verdict and the pillar-by-pillar reasoning.
What is Progyny, Inc.'s moat score?: Progyny, Inc. (PGNY) has a moat score of 52/100. The score is a weighted average of five pillar ratings: network effects, switching costs, intangible assets, cost advantages, and efficient scale. A higher score means the competitive advantages MoatScan AI identifies are wider and more durable.Sign in free to see each pillar rating, the Moat Type verdict and the moat trend.
Is PGNY stock overvalued or undervalued?: MoatScan AI answers this by estimating PGNY's intrinsic value with a discounted cash flow (DCF) model, then comparing that estimate to the current market price. A share price meaningfully below the estimate is flagged undervalued; meaningfully above it, overvalued. The estimate updates with each new financial analysis.Sign in free to see the fair value estimate, the implied upside or downside, and the verdict.
What is Progyny, Inc.'s fair value estimate?: MoatScan AI derives Progyny, Inc.'s (PGNY) fair value per share from a discounted cash flow (DCF) model built on the company's reported financials, analyst growth forecasts, and a discount rate reflecting its cost of capital. The Financial Analysis tab shows the estimate alongside every assumption behind it.Sign in free to see the estimate and the full assumptions behind it.

Disclaimer: The analysis on this page is generated by AI and is provided for informational purposes only. It does not constitute financial advice, investment recommendations, or an offer to buy or sell any security. Always conduct your own due diligence and consult a qualified financial adviser before making any investment decisions.

PGNY$25.96

Sign in to see the full analysis

Sign in to see the full analysis

Sign In to Run AI-Powered Technical Analysis

Frequently asked questions about Progyny, Inc.

Other Narrow Moat companies